A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model

Angiogenesis

Volumn 5, Issue 1-2, 2002, Pages 35-44

  Zhang, Wei ^a,b   Ran, Sophia ^a   Sambade, M ^a   Huang, Xianming ^a   Thorpe, Philip E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Maryland General Hospital   (United States)

Author keywords

Angiogenesis; Breast cancer; Microvasculature; Vascular endothelial growth factor; VEGF antibody

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; INHIBITION KINETICS; MAMMARY GLAND FUNCTION; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA; MUS MUSCULUS;

EID: 0036941125     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021540120521     Document Type: Article

References (67)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Algire GH, Chalkley HW, Legallais FY, Park HD. Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945; 6: 73-85.
3. Gimbrone MA, Jr, Cotran R, Leapman S, Folkman J. Tumor growth and neovascularization: An experimental model using rabbit cornea. J Natl Cancer Inst 1974; 52: 413-27.
4. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
5. Fidler IJ. Angiogenesis and cancer metastasis. Cancer J Sci Am 2000; 6 (Suppl 2): S134-41.
6. Fidler IJ, Rumar R, Bielenberg DR, Ellis LM. Molecular determinants of angiogenesis in cancer metastasis. Cancer J Sci Am 1998; 4: S58-66.
7. McNamara DAA, Harmey JH, Walsh TN et al. Significance of angiogenesis in cancer therapy. Br J Surg 1998; 85: 1044-55.
8. Brown LF. Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Path 1995; 1: 86-91.
9. Warren RS, Yuan H, Matli MR et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789-97.
10. Boocock CA, Charnock-Jones DS, Sharkey AM. Expression of vascular endothelial growth factor and its receptors FLT and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506-16.
11. Berkman RA, Merrill MJ, Reinhold WC et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993; 91: 153-9.
12. Connolly DT, Heuvelman DM, Nelson R et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470-8.
13. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-8.
14. Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989; 86: 7311-5.
15. Keck PJ, Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-12.
16. Leung DW. Cachianes G, Kuang W-J et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
17. Conn G, Bayne ML. Soderman DD et al. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 1990; 87: 2628-32.
18. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endo Rev 1992; 13: 18-32.
19. Senger DR, Vandewater L, Brown LF et al. Vascular permeability factor (VPF,VEGF) in tumor biology. Cancer Meta Rev 1993; 12: 303-24.
20. Dvorak HF, Sioussat TM, Brown LF et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors - concentration in tumor blood vessels. J Exp Med 1991; 174: 1275-8.
21. Klement G, Baruchel S, Rak J et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-24.
22. Bruns CJ, Liu W, Davis DW et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000; 89: 488-99.
23. Tran J, Rak J, Sheehan C et al. Marked induction of the IAP family antiapoptotic proteins surviving and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999; 264: 781-8.
24. Meyer M, Clauss M, Lepple-Wienhues A et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 1999; 18(2): 363-74.
25. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem 2000; 275(35): 26690-5.
26. Ahmed A, Dunk C, Kniss D, Wilkes M. Role of VEGF receptor-1 (FLT-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells. Lab Invest 1997; 76(6): 779-91.
27. Siemeister G, Martiny-Baron G, Marme D. The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities. Cancer Metastasis Rev 1998; 17: 241-8.
28. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4.
29. Asano K, Yukita A, Matsumoto T et al. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 1998; 17: 185-90.
30. Borgstrom P, Bourdon MA, Hillan KJ et al. Neutralizing antivascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998; 35: 1-10.
31. Asano M, Yukita A, Suzuki H. Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Cancer Res 1999; 90: 93-100.
32. Gerber H-P, Kowalski J, Sherman D et al. Complete inhibition of rabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000; 60: 6253-8.
33. Soh EY, Eigelberger MS, Kim KJ et al. Neutralizing vascular endothelial growth factor activity inhibits thyrpid cancer growth in vivo. Surgery 2000; 128: 1059-65.
34. Sledge GW, Jr, Miller K, Novotny W et al. A phase II trial of single-agent rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients within relapsed metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19: 3a.
35. Bergsland E, Fehrenbacher L, Meropol NJ et al. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastic colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 939.
36. DeVore RF, Fehrenbacher L, Herbst RS et al. A randomized phase II trial comparing rhumab VEGF (Recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2000; 19: 485a (Abstr 1896).
37. Gordon MS, margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50.
38. Brekken RA, Huang X, King S, Thorpe PE. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998; 58: 1952-9.
39. Brekken RA, Overholser J, Stastny VA et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000; 60: 5117-24.
40. Leppink DM, Bishop DK, Sedmak DD et al. Inducible expression of an endothelial cell antigen on murine myocardial vasculature in association with interstitial cellular infiltration. Transplantation 1989; 48(5): 874-7.
41. Rouan SK, Otterness IG, Cunningham AC et al. Reversal of colchicines-induced mitotic arrest in Chinese hamster cells with a colchicines-specific monoclonal antibody. Am J Pathol 1990; 137: 779-87.
42. Burrows FJ, Watanabe Y, Thorpe PE. A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. Cancer Res 1992; 52: 5954-62.
43. Ran S, Gao B, Duffy S et al. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998; 58(20): 4646-53.
44. Benjamin LE, Golijanin D, Itin A et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103(2): 159-65.
45. Huang X, Gottstein C, Brekken RA, Thorpe PE. Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. Biochem Biophys Res Commun 1998; 252: 643-48.
46. Morrow KJ, Unuvar E, King SW, Mleczko JB. Techniques for the production of monoclonal and potyclonal antibodies. In Hayat MA (ed): Colloidal Gold: Principles, Methods, and Applications. Orlando, Florida: Academic Press, 1990; 31-57.
47. Fidler IJ. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 1986; 5: 29-51.
48. Ahlering TE, Jones PA. A new in vivo model to study invasion and metastasis of a human bladder carcinoma. Cancer Res 1987; 47: 6660-5.
49. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorgenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50: 717-21.
50. Zhang RD, Fidler IJ, Price JE. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Inv Metastasis 1991; 11: 204-15.
51. Dunk C, Ahmed A. Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells. Am J Pathol 2001; 158: 265-73.
52. Yoshiji H, Harris SR, Thorgeirsson U. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997; 57(18): 3924-8.
53. Shen BQ, Lee DY, Gerber H-P et al. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth in vitro. J Biol Chem 1998; 273(45): 29979-85.
54. Wilting J, Birkenhager R, Eichmann A et al. VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane. Dev Biol 1996: 176(1): 76-85.
55. Kremer C, Breier G, Risau W, Plate KH. Up-regulation of flk-1/ vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res 1997; 57(17): 3852-9.
56. Arbiser JL, Larsson H, Claesson-Welsh L et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGF 1 and VEGFR-2 in vivo. Am J Pathol 2000; 156(4): 1469-76.
57. Hart IR, Fidler IJ. Role of organ selectivity in determination of metastatic patterns of B16 melanoma. Cancer Res 1981; 41: 1281-5.
58. Kalebic T, Garbisa S, Glaser B, Liotta LA. Basement membrane collagen: Degradation by migrating endothelial cells. Science 1983; 221: 281-3.
59. Mori S, Ueda T, Kuratsu S et al. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-4700 in murine osteosarcoma. Int J Cancer 1995; 6: 148-52.
60. Fidler IJ, Gersten DM, Hart IR. The biology of cancer invasion and metastasis. Acv Cancer Res 1978; 28: 149-250.
61. Fidler IJ. Critical factors in the biology of human cancer metastasis: Twenty-eight G.H.A. Clowes Memorial Award Lecture. Cancer Res 1990; 50: 6130-9.
62. Itakura J, Ishiwati T, Shen B et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000; 85: 27-34.
63. Baek JH, Jang JE, Kang CM et al. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 2000; 19: 4621-31.
64. Gordon MS, Margolin KA, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Pharmacol 2000; 19(3): 843-850.
65. Barleon B, Sozzani S, Zhou D et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87(8): 3336-43.
66. Akuzawa N, Kurabayashi M, Ohyama Y et al. Zinc finger transcription factor Egr-1 activates Flt-1 gene expression in THP-1 cells on induction for macrophage differentiation. Arterioscler Thromb Vasc Biol 2000; 20(2): 377-84.
67. Clauss M, Gerlach M, Gerlach H et al. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotesmonocyte migration. J Exp Med 1990; 172(6): 1535-45.